Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Clinical Cooperation Unit Neurooncology

Prof. Dr. Wolfgang Wick

MRI profile of a glioblastoma patient

The Clinical Cooperation Unit (CCU) Neurooncology is a cooperation between the German Cancer Research Center (DKFZ) and the Heidelberg University Hospital Neurology Department. The overarching goal of the research is to understand the fundamental biology of brain tumors and rapidly translate the pre-clinical observations back into the clinic in a bench-to-bedside approach. The CCU Neurooncology is structured into two subgroups. Research in the CCU Neurooncology (Prof. Dr. Wolfgang Wick) focuses on understanding intrinsic glioblastoma and CNS lymphoma treatment resistance mechanisms and additionally investigates the contribution of stem cells and the tumor microenvironment therein. Clinical trials and tumor samples derived within this frame serve as a major resource to understand the interaction between standard-of-care treatments and molecularly defined treatments which highlights the translational research focus of the group. The research group Experimental Neurooncology (Prof. Dr. Frank Winkler) is addressing the question of how interactions between the nervous system and cancer, and cancer-intrinsic neural mechanisms, drive brain tumor initiation, growth, invasion and resistance. This field is called "Cancer Neuroscience” and has led to paradigmatic discoveries with clinical implications. Bespoke technologies, including intravital microscopy methods, are developed to interrogate the malignant networks and their communication strategies - in incurable gliomas, brain metastases, and cancers outside the brain.

More detailed information about each subgroup can be found on the respective websites.

CCU Neurooncology
RG Experimental Neurooncology


Prof. Dr. Wolfgang Wick
Neurooncology (B320)
Neurologische Klinik
& Nationales Centrum für Tumorerkrankungen
Im Neuenheimer Feld 400
69120 Heidelberg
Tel: +49 6221 56 7075
Fax: +49 6221 56 7554

Selected Publications

  • Hausmann D, Hoffmann D C, Venkataramani V, Jung E, Horschitz S, Tetzlaff S K, Jabali A, Hai L, Kessler T, Azorín D D, Weil S, Kourtesakis A, Sievers P, Habel A, Breckwoldt M O, Karreman M A, Ratliff M, Messmer J M, Yang Y, Reyhan E, Wendler S, Löb C, Mayer C, Figarella K, Osswald M, Solecki G, Sahm F, Garaschuk O, Kuner T, Koch P, Schlesner M, Wick W and Winkler F. Autonomous rhythmic activity in glioma networks drives brain tumour growth. Nature 2023 613(7942):179-186, DOI: 10.1038/s41586-022-05520-4 Available via:
  • Hai L*, Hoffmann D C*, Mandelbaum H, Xie R, Ito J, Jung E, Weil S, Sievers P, Venkataramani V, Azorín D D, Ernst K, Reibold D, Will R, Suvà M L, Herold-Mende C, Sahm F, Winkler F, Schlesner M, Wick W, Kessler T. A connectivity siganture for glioblastoma. Biorxiv 2021, DOI: 10.1101/2021.11.07.465791, *contributed equally
  • Karreman MA, Bauer AT, Solecki G, Berghoff AS, Mayer CD, Frey K, Hebach N, Feinauer MJ, Schieber NL, Tehranian C, Mercier L, Singhal M, Venkataramani V, Schubert MC, Hinze D, Hölzel M, Helfrich I, Schadendorf D, Schneider SW, Westphal D, Augustin HG, Goetz JG, Schwab Y, Wick W, Winkler F. Active remodeling of capillary endothelium via cancer cell-derived MMP9 promotes metastatic brain colonization. Cancer Res 2023, DOI: 10.1158/0008-5472.CAN-22-3964. Epub ahead of print.
  • Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones D T W, Pfister S M, Sahm F, Platten M. N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. Neuro Oncol. 2019 Jan 1; 23(1):95-105. DOI: 10.1090/neuonc/noy161
to top
powered by webEdition CMS